Pfizer gained 1% in premarket trading after signing an exclusive global deal with YaoPharma, a Shanghai Fosun Pharma unit, to develop YP05002, a small-molecule GLP-1 drug for chronic weight management. YaoPharma will finish Phase 1 before transferring rights. The company will receive $150M upfront and up to $1.94B in milestones. Pfizer said the deal strengthens its cardiometabolic pipeline.